Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines.

Autor: Wang R; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America., Oliveira LVN; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America., Hester MM; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America., Carlson D; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America., Christensen D; Statens Serum Institut, Copenhagen, Denmark., Specht CA; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America., Levitz SM; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
Jazyk: angličtina
Zdroj: PLoS pathogens [PLoS Pathog] 2024 Jul 08; Vol. 20 (7), pp. e1012220. Date of Electronic Publication: 2024 Jul 08 (Print Publication: 2024).
DOI: 10.1371/journal.ppat.1012220
Abstrakt: The fungal infection, cryptococcosis, is responsible for >100,000 deaths annually. No licensed vaccines are available. We explored the efficacy and immune responses of subunit cryptococcal vaccines adjuvanted with Cationic Adjuvant Formulation 01 (CAF01). CAF01 promotes humoral and T helper (Th) 1 and Th17 immune responses and has been safely used in human vaccine trials. Four subcutaneous vaccines, each containing single recombinant Cryptococcus neoformans protein antigens, partially protected mice from experimental cryptococcosis. Protection increased, up to 100%, in mice that received bivalent and quadrivalent vaccine formulations. Vaccinated mice that received a pulmonary challenge with C. neoformans had an influx of leukocytes into the lung including robust numbers of polyfunctional CD4+ T cells which produced interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), and interleukin (IL)-17 upon ex vivo antigenic stimulation. Cytokine-producing lung CD8+ T cells were also found, albeit in lesser numbers. A significant, durable IFNγ response was observed in the lungs, spleen, and blood. Moreover, IFNγ secretion following ex vivo stimulation directly correlated with fungal control in the lungs. Thus, we have developed multivalent cryptococcal vaccines which protect mice from experimental cryptococcosis using an adjuvant which has been safely tested in humans. These preclinical studies suggest a path towards human cryptococcal vaccine trials.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje